Inhibrx Biosciences, Inc. also files under INBX; those filings are included.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 8, 2026 | Forsyth Douglas | Director | Buy(P) | 3K | $114.65 | $287K |
| Sep 8, 2026 | Lappe Mark | Chief Executive Officer, Director | Buy(P) | 7K | $100.64 | $665K |
| Sep 8, 2026 | Lappe Mark | Chief Executive Officer, Director | Buy(P) | 1K | $107.12 | $118K |
| Sep 8, 2026 | Lappe Mark | Chief Executive Officer, Director | Buy(P) | 500 | $108.24 | $54K |
| Sep 8, 2026 | Lappe Mark | Chief Executive Officer, Director | Buy(P) | 1K | $111.88 | $136K |
| Sep 8, 2026 | Lappe Mark | Chief Executive Officer, Director | Buy(P) | 10K | $112.28 | $1.1M |
| Sep 8, 2026 | Kayyem Jon Faiz | Director | Buy(P) | 5K | $113.52 | $568K |
| Sep 8, 2026 | Lappe Mark | Chief Executive Officer, Director | Buy(P) | 6K | $99.29 | $585K |
| Jun 3, 2026 | Vuori Kristiina MD | Director | Grant(A) | 15K | — | $0 |
| Jun 3, 2026 | Forsyth Douglas | Director | Grant(A) | 15K | — | $0 |
| Jun 3, 2026 | Manhard Kimberly | Director | Grant(A) | 15K | — | $0 |
| Jun 3, 2026 | Kayyem Jon Faiz | Director | Grant(A) | 15K | — | $0 |
| Apr 24, 2026 | Matly David | President | Grant(A) | 50K | — | $0 |
| Oct 7, 2025 | Viking Global Opportunities Parent GP LLC | 10% Owner | Sell(S) | 309K | $32.25 | $10.0M |
| Oct 7, 2025 | Viking Global Opportunities Parent GP LLC | 10% Owner | Sell(S) | 16K | $32.25 | $526K |
| Oct 7, 2025 | Viking Global Opportunities Parent GP LLC | 10% Owner | Sell(S) | 25K | $32.25 | $808K |
| May 28, 2025 | Manhard Kimberly | Director | Grant(A) | 15K | — | $0 |
| May 28, 2025 | Forsyth Douglas | Director | Grant(A) | 15K | — | $0 |
| May 28, 2025 | Kayyem Jon Faiz | Director | Grant(A) | 15K | — | $0 |
| May 28, 2025 | Vuori Kristiina MD | Director | Grant(A) | 15K | — | $0 |
| Apr 1, 2025 | Deck Kelly | Chief Financial Officer | Grant(A) | 15K | — | $0 |
| Apr 1, 2025 | Matly David | President | Grant(A) | 50K | — | $0 |
| Mar 27, 2025 | Kayyem Jon Faiz | Director | Gift(G) | 90K | — | $0 |
| Dec 16, 2024 | Kayyem Jon Faiz | Director | Gift(G) | 250K | — | $0 |
| Dec 16, 2024 | Kayyem Jon Faiz | Director | Gift(G) | 250K | — | $0 |
| Dec 16, 2024 | Kayyem Jon Faiz | Director | Gift(G) | 500K | — | $0 |
| Dec 6, 2024 | Kayyem Jon Faiz | Director | Gift(G) | 52K | — | $0 |
| Nov 20, 2024 | Kayyem Jon Faiz | Director | Buy(P) | 19K | $14.19 | $266K |
| Nov 20, 2024 | Kayyem Jon Faiz | Director | Buy(P) | 19K | $14.19 | $266K |
| Nov 19, 2024 | Kayyem Jon Faiz | Director | Buy(P) | 35K | $14.23 | $496K |
| Nov 19, 2024 | Kayyem Jon Faiz | Director | Buy(P) | 35K | $14.23 | $496K |
| Oct 3, 2024 | Vuori Kristiina MD | Director | Buy(P) | 7K | $15.00 | $100K |
| Sep 16, 2024 | Lappe Mark | Chief Executive Officer, Director | Buy(P) | 13K | $17.13 | $223K |
| Sep 12, 2024 | Lappe Mark | Chief Executive Officer, Director | Buy(P) | 27K | $15.05 | $406K |
| Sep 11, 2024 | Vuori Kristiina MD | Director | Buy(P) | 6K | $15.07 | $97K |
| Sep 10, 2024 | Lappe Mark | Chief Executive Officer, Director | Buy(P) | 9K | $15.19 | $129K |
| Sep 10, 2024 | Vuori Kristiina MD | Director | Buy(P) | 179 | $15.00 | $3K |
| Sep 9, 2024 | Lappe Mark | Chief Executive Officer, Director | Buy(P) | 10K | $15.21 | $144K |
| Sep 6, 2024 | Lappe Mark | Chief Executive Officer, Director | Buy(P) | 26K | $15.29 | $398K |
| Sep 3, 2024 | Lappe Mark | Chief Executive Officer, Director | Buy(P) | 15K | $15.66 | $239K |
| Sep 3, 2024 | Lappe Mark | Chief Executive Officer, Director | Buy(P) | 5K | $16.31 | $77K |
| Aug 30, 2024 | Lappe Mark | Chief Executive Officer, Director | Buy(P) | 10K | $14.02 | $140K |
| Aug 29, 2024 | Lappe Mark | Chief Executive Officer, Director | Buy(P) | 10K | $14.03 | $140K |
| Aug 29, 2024 | Vuori Kristiina MD | Director | Buy(P) | 7K | $14.00 | $100K |
| Aug 28, 2024 | Manhard Kimberly | Director | Buy(P) | 10K | $13.98 | $140K |
| Aug 23, 2024 | Forsyth Douglas | Director | Buy(P) | 60K | $14.07 | $842K |
| Aug 22, 2024 | Forsyth Douglas | Director | Buy(P) | 15K | $12.89 | $196K |
| Aug 21, 2024 | Lappe Mark | Chief Executive Officer, Director | Buy(P) | 13K | $12.93 | $167K |
| Aug 20, 2024 | Lappe Mark | Chief Executive Officer, Director | Buy(P) | 27K | $12.97 | $351K |
| Jun 24, 2024 | Kayyem Jon Faiz | Director | Gift(G) | 10K | — | $0 |
| Jun 24, 2024 | Kayyem Jon Faiz | Director | Gift(G) | 89K | — | $0 |
| Jun 24, 2024 | Kayyem Jon Faiz | Director | Gift(G) | 10K | — | $0 |
| Jun 5, 2024 | Kayyem Jon Faiz | Director | Buy(P) | 8K | $17.89 | $148K |
| Jun 5, 2024 | Kayyem Jon Faiz | Director | Buy(P) | 49K | $17.23 | $849K |
| Jun 4, 2024 | Kayyem Jon Faiz | Director | Buy(P) | 24K | $18.24 | $433K |
| Jun 4, 2024 | Kayyem Jon Faiz | Director | Buy(P) | 65K | $17.44 | $1.1M |
| Jun 3, 2024 | Kayyem Jon Faiz | Director | Buy(P) | 47K | $16.61 | $777K |
| Jun 3, 2024 | Kayyem Jon Faiz | Director | Buy(P) | 81K | $17.90 | $1.4M |
| May 31, 2024 | Kayyem Jon Faiz | Director | Buy(P) | 70K | $16.14 | $1.1M |
| May 30, 2024 | Manhard Kimberly | Director | Grant(A) | 30K | — | $0 |
| May 30, 2024 | Eckelman Brendan P. | Chief Scientific Officer | Grant(A) | 175K | — | $0 |
| May 30, 2024 | Vuori Kristiina MD | Director | Grant(A) | 30K | — | $0 |
| May 30, 2024 | Kayyem Jon Faiz | Director | Grant(A) | 30K | — | $0 |
| May 30, 2024 | Deck Kelly | Chief Financial Officer | Grant(A) | 175K | — | $0 |
| May 30, 2024 | Forsyth Douglas | Director | Grant(A) | 30K | — | $0 |
| May 30, 2024 | Lappe Mark | Chief Executive Officer, Director | Grant(A) | 300K | — | $0 |
| May 29, 2024 | Eckelman Brendan P. | Chief Scientific Officer | Grant(A) | 40K | — | — |
| May 29, 2024 | Eckelman Brendan P. | Chief Scientific Officer | Grant(A) | 434K | — | — |
| May 29, 2024 | Kayyem Jon Faiz | Director | Grant(A) | 6K | — | — |
| May 29, 2024 | Inhibrx, Inc. | 10% Owner | Other(J) | 13.3M | — | — |
| May 29, 2024 | Kayyem Jon Faiz | Director | Grant(A) | 806K | — | — |
| May 29, 2024 | Lappe Mark | Chief Executive Officer, Director | Grant(A) | 622K | — | — |
| May 29, 2024 | Lappe Mark | Chief Executive Officer, Director | Grant(A) | 125K | — | — |
| May 29, 2024 | Lappe Mark | Chief Executive Officer, Director | Grant(A) | 15K | — | — |
| May 29, 2024 | Kayyem Jon Faiz | Director | Grant(A) | 6K | — | — |
| May 29, 2024 | Forsyth Douglas | Director | Grant(A) | 150K | — | — |
| May 29, 2024 | Eckelman Brendan P. | Chief Scientific Officer | Grant(A) | 40K | — | — |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Issuer: Inhibrx Biosciences, Inc., SEC CIK 0002007919. The symbol on a Form 4 is typed by the filer, so this page follows the issuer with the newest filing under INXB and shows every filing by that issuer (also filed as INBX).
Coverage: Form 4 filings indexed 2006-01-02 → 2026-09-09. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).
Connected pages for INXB